Vivimed Labs surges on plan to acquire Finoso Pharma for Rs 15 crore

15 Feb 2013 Evaluate

Vivimed Labs is currently trading at Rs. 325.85, up by 8.15 points or 2.57% from its previous closing of Rs. 317.70 on the BSE.

The scrip opened at Rs. 320.00 and has touched a high and low of Rs. 327.50 and Rs. 320.00 respectively. So far 13414 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 444.00 on 18-Apr-2012 and a 52 week low of Rs. 310.00 on 14-Feb-2013.

Last one week high and low of the scrip stood at Rs. 334.00 and Rs. 310.00 respectively. The current market cap of the company is Rs. 454.46 crore.

The promoters holding in the company stood at 45.15% while Institutions and Non-Institutions held 3.57% and 51.28% respectively. 

Vivimed Labs has proposed to acquire Finoso Pharma for a total consideration of Rs 15 crore comprising cash, stock and deferred payment. Post acquisition, Finoso will become Vivimed’s research and development (R&D) unit to support innovators, generics and licensing efforts.

Finoso Pharma is a pharmaceutical development services company focused on formulations product development efforts for multiple markets and develops globally accepted dossiers.

Vivimed Labs Share Price

5.75 0.00 (0.00%)
31-Jul-2023 18:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1267.15
Cipla 1498.90
Zydus Lifesciences 924.35
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×